The role of setting for ketamine abuse: clinical and preclinical evidence.
about
Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant actionKetamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant propertiesFive potential therapeutic agents as antidepressants: a brief review and future directions.The role of TNF-α in regulating ketamine-induced hippocampal neurotoxicity.Pharmacological and non-pharmacological factors that regulate the acquisition of ketamine self-administration in rats.Differential vulnerability to relapse into heroin versus cocaine-seeking as a function of setting.Intravenous self-administration of benzydamine, a non-steroidal anti-inflammatory drug with a central cannabinoidergic mechanism of action.
P2860
Q36020138-5D99D5E0-7F7E-4041-9BD2-A04C5EB392E7Q37330681-631C717D-9927-4DD7-BB40-DBD4D020DCFBQ38574831-14ACC3F9-0367-4F17-9252-060B1A467D8DQ41453808-4B780958-AB14-4FE9-95CC-7EAF91DB9547Q47650736-F0C4839E-F7B7-4009-9419-1D340290DEF2Q47751114-9CB7390D-9D42-45E7-8087-479AD2D338ABQ47910231-78D90005-7F90-4DF9-8373-FE258445555A
P2860
The role of setting for ketamine abuse: clinical and preclinical evidence.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The role of setting for ketamine abuse: clinical and preclinical evidence.
@ast
The role of setting for ketamine abuse: clinical and preclinical evidence.
@en
type
label
The role of setting for ketamine abuse: clinical and preclinical evidence.
@ast
The role of setting for ketamine abuse: clinical and preclinical evidence.
@en
prefLabel
The role of setting for ketamine abuse: clinical and preclinical evidence.
@ast
The role of setting for ketamine abuse: clinical and preclinical evidence.
@en
P2093
P1476
The role of setting for ketamine abuse: clinical and preclinical evidence.
@en
P2093
Aldo Badiani
Maria Meringolo
Maria Teresa De Luca
Primavera Alessandra Spagnolo
P304
P356
10.1515/REVNEURO-2012-0078
P577
2012-01-01T00:00:00Z